Patents by Inventor Gary H. Cohen

Gary H. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9089537
    Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: July 28, 2015
    Assignees: The Trustees of the University of Pennslyvania, Juvaris Biotherapeutics, Inc.
    Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
  • Publication number: 20130171234
    Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
    Type: Application
    Filed: February 25, 2011
    Publication date: July 4, 2013
    Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 8124105
    Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: February 28, 2012
    Assignees: The Trustees of the University of Pennsylvania, The United States of America as represented by the Department of Health and Human Services
    Inventors: Gary H. Cohen, Roselyn J. Eisenbert, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
  • Publication number: 20100021484
    Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
    Type: Application
    Filed: June 23, 2009
    Publication date: January 28, 2010
    Inventors: Gary H. Cohen, Roselyn J. Eisenbert, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
  • Patent number: 7560116
    Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: July 14, 2009
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
  • Publication number: 20040259773
    Abstract: The invention includes antiherpesviral peptides and methods of generating the same.
    Type: Application
    Filed: March 1, 2004
    Publication date: December 23, 2004
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
  • Patent number: 6699481
    Abstract: The invention includes antiherpesviral peptides and method of generating the same.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: March 2, 2004
    Assignees: The Trustees of the University of Pennsylvania, Northwestern University
    Inventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
  • Patent number: 6641818
    Abstract: A cellular herpesvirus entry protein, or a mutant, a homolog, a derivative, a variant or a biologically active fragment thereof, suspended in a pharmaceutically active carrier in an amount effective to inhibit entry of an alphaherpesvirus into a cell, wherein the cellular herpesvirus entry protein is a member of the immunoglobulin superfamily, is provided and method of use thereof
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 4, 2003
    Assignee: Northwestern University
    Inventors: Patricia G. Spear, Morgyn S. Warner, Robert J. Geraghty, Wanda M. Martinez, Rebecca I. Montgomery, Gary H. Cohen, Roselyn J. Eisenberg, Charles J. Whitbeck, Claude Krummenacher
  • Publication number: 20030152583
    Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
    Type: Application
    Filed: February 20, 2003
    Publication date: August 14, 2003
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
  • Patent number: 6541459
    Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: April 1, 2003
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
  • Publication number: 20020119165
    Abstract: The invention includes antiherpesviral peptides and method of generating the same.
    Type: Application
    Filed: February 16, 2001
    Publication date: August 29, 2002
    Inventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
  • Patent number: 6156319
    Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: December 5, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
  • Patent number: 5814486
    Abstract: The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: September 29, 1998
    Assignee: Competitive Technologies, Inc.
    Inventors: Gary H. Cohen, Roselyn T. Eisenberg, Anthony Nicola
  • Patent number: 5654174
    Abstract: The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Competitive Technologies, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg, Anthony Nicola
  • Patent number: 5149660
    Abstract: Disclosed are diagnostic reagents for use in detection of Herpes Simplex Virus Type 1 antibodies or Herpes Simplex Virus Type 2 antibodies comprising novel Herpes Simplex Virus envelope glycoproteins gD-1 and gD-2, immunologically active fragments thereof, immunologically synthetic replicas, thereof, and specific polypeptides comprising specific amino acid sequences.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: September 22, 1992
    Assignee: University Patents, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 4762708
    Abstract: Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunoadsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid sequences which are: (1) substantially common to both gD-1 and gD-2; cumulatively hydrophilic in nature; and (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification.
    Type: Grant
    Filed: February 4, 1983
    Date of Patent: August 9, 1988
    Assignee: University Patents, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 4745182
    Abstract: Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)].
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: May 17, 1988
    Assignee: University Patents, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 4709011
    Abstract: Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunodsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex virus disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid squences which are: (1) substantially common to both gD-1 and gD-2; (2) cumulatively hydrophilic in nature; (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification. Vaccines incorporating the synthetic polypeptides give rise to protective immunological responses, e.g., they protect mice against Herpes simplex.
    Type: Grant
    Filed: May 15, 1985
    Date of Patent: November 24, 1987
    Assignee: University Patents, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg